Luisa M. Stamm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luisa M. Stamm has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Man-Fung Yuen
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
2 shared publications Natarajan Ravendhran
Gastrohealth, Catonsville, MD, USA
2 shared publicationsAlnoor Ramji
Gastrointestinal Research Institute, Vancouver, BC, Canada
1 shared publicationAngel Alsina
1 shared publication- Anuj Gaggar
Assembly Biosciences, Inc. South San Francisco California USA
1 shared publication - Brian B. Borg
Department of Digestive Diseases, University of Mississippi Medical Center, Jackson, Mississippi
1 shared publication
Latest Publications
- Open Access
- 26 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (4) , 983-990
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes
Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.
- 26 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (4) , 983-990
Open AccessChronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes
Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.
- Open Access
- 11 June 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (5) , 1265-1275
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
- 11 June 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (5) , 1265-1275
Open AccessSafety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
- Open Access
- 1 May 2019
- Published by Elsevier in Gastroenterology
- Vol. 156 (6)
953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis
- 1 May 2019
- Published by Elsevier in Gastroenterology
- Vol. 156 (6)
Open Access953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S513-S514
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy
- 1 January 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (1) , S513-S514
SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy